Iloprost in Acute Respiratory Distress Syndrome

Summary

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Timeline

Start

2019-06-25

Primary completion

2021-05-14

Completion

2021-08-14

Publications

• Bernard A, Serna-Higuita LM, Althaus K, Rosenberger P, Vohringer R, Korner A, Haeberle H, Eggstein C, Bakchoul T, Margraf A, Fodi C, Zarbock A, Koeppen M, Mirakaj V. Diminished plasma levels of GPIb-alpha predict mortality in a prospective ARDS cohort. Front Med (Lausanne). 2026 Apr 24;13:1711751. doi: 10.3389/fmed.2026.1711751. eCollection 2026.
• Haeberle HA, Calov S, Martus P, Serna-Higuita LM, Koeppen M, Goll A, Bernard A, Zarbock A, Meersch M, Weiss R, Mehrlander M, Marx G, Putensen C, Bakchoul T, Magunia H, Nieswandt B, Mirakaj V, Rosenberger P. Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial. Respir Res. 2023 Feb 18;24(1):58. doi: 10.1186/s12931-023-02346-0.
• Haeberle H, Prohaska S, Martus P, Straub A, Zarbock A, Marx G, Zago M, Giera M, Koeppen M, Rosenberger P. Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study. Trials. 2020 Mar 4;21(1):242. doi: 10.1186/s13063-020-4163-0.

Drugs

Indications